Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as "relapsing" or "progressive." An international study, published on August 20, 2025, in Nature Medicine under ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

Explore the unique challenges faced by women with Multiple Sclerosis and the need for holistic care solutions in India.

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a ...

People with multiple sclerosis (MS) may have symptoms that relapse, steadily progress over time, or progress from the onset of symptoms. MS is a disease of the central nervous system (CNS), which ...

Researchers say delayed diagnosis, lack of awareness, expensive treatment, and poor access to neurological care continue affecting thousands of patients across the world, including India. Experts say ...

Multiple Sclerosis (MS) is a chronic neurological autoimmune disease of the central nervous system that affects every individual differently. In the case of MS, it attacks the protective covering of ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial for the most common form of the disease. The Swiss pharmaceutical company said Monday ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...